JAZZ Earnings

JAZZ reported its earnings on 2026-02-24, showcasing a revenue of 1.20B against an estimate of 1.18B, resulting in a 1.44% surprise. The EPS was 6.64, surpassing the expected 6.62 by 0.3%. The stock experienced a 13.23% price change on the earnings day and a 9.57% change over the next five days, reflecting market reactions to the results.

Following JAZZ's earnings announcement on 2026-02-24, the stock price moved by 13.23% on the day of the release. Over the subsequent five days, it saw a 9.57% change. Historically, JAZZ's stock price tends to shift by an average of -3.12% in the 10 days leading up to earnings and 2.78% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate JAZZ's annual revenue to reach 984.62M, while the EPS is projected at 4.34. These estimates reflect recent revisions, with revenue estimates revised upward by 0.01% and EPS estimates revised upward by 0.05% over the past three months, indicating analyst expectation in the company's performance.

The correlation between JAZZ's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.01%, while EPS estimates moved revised upward by 0.05%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, JAZZ's stock price typically moves by -3.12% in the 10 days before its earnings and 2.78% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 4.34 and revenue of 984.62M.

Jazz Pharmaceuticals reported strong financial performance with a 12% revenue increase and an 8% rise in net income, driven by key product sales. The company showed improved gross margins and cash flow, despite higher R&D expenses. No concerns were raised in the Q&A session, and strategic initiatives like strong pipeline development and anticipated product launches suggest a positive outlook. The lack of dividend or buyback announcements does not detract from the overall positive sentiment. With no market cap data, the prediction leans positive based on financial strength and strategic positioning.